HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Radical prostatectomy in high-risk prostate cancer: incidence of specimen-confined disease (pT2-pT3a N0R0) and outcomes.

AbstractINTRODUCTION:
Radical prostatectomy (RP) in patients with high-risk prostate cancer (PC) [prostate specific antigen (PSA) ≥ 20 ng/mL, and/or Gleason score ≥ 8, and/or cT3a disease] is considered an optional therapy, usually as a part of multimodal approach. Aim of the study is to evaluate the outcome of radical prostatectomy in case of specimen-confined (SC) disease and to compare it with patients with pathological locally-advanced disease.
MATERIALS AND METHODS:
Data from 176 consecutive patients with high-risk prostate cancer who underwent RP as initial therapy were analyzed, identifying subjects with specimen-confined disease (i.e. negative margins and negative lymph-nodes) in which RP was considered as monotherapy, and comparing oncological outcomes to patients with pathological non-SC disease, in which RP was considered as the first step of a multimodal approach.
RESULTS:
In high-risk prostate cancer, pathological report showed the presence of specimen-confined disease in 28.3% of cases. At univariate analysis, age and PSA correlate with the presence of SC disease at radical prostatectomy, while at multivariate analysis only PSA was a significant predictor of SC disease. At 5 years, Kaplan-Meier estimation of biochemical-free and cancer-specific survival was 56.2% and 97.7% vs 40.8% and 92.8% in specimen-confined disease and non-specimen-confined disease, respectively.
CONCLUSIONS:
High-risk prostate cancer presents challenges for uro-oncologists since standard treatment is still under debate. One third of patients will present with specimen-confined disease, for which radical prostatectomy represents the sole, initial curative therapy; RP as multimodal therapy in patients without SC disease permits excellent long-term oncological outcomes.
AuthorsLuigi Mearini, Elisabetta Nunzi, Vittorio Bini, Luca Lepri, Raffaella Bruno, Massimo Porena
JournalUrologia (Urologia) 2014 Apr-Jun Vol. 81 Issue 2 Pg. 125-32 ISSN: 1724-6075 [Electronic] United States
PMID24474543 (Publication Type: Journal Article)
Topics
  • Adenocarcinoma (pathology, radiotherapy, secondary, surgery)
  • Aged
  • Bone Neoplasms (diagnostic imaging, secondary)
  • Combined Modality Therapy
  • Disease-Free Survival
  • Follow-Up Studies
  • Humans
  • Kaplan-Meier Estimate
  • Lymph Node Excision
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Prostatectomy (methods)
  • Prostatic Neoplasms (pathology, radiotherapy, surgery)
  • Radionuclide Imaging
  • Radiotherapy, Adjuvant
  • Radiotherapy, Conformal
  • Retrospective Studies
  • Salvage Therapy
  • Tomography, X-Ray Computed
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: